Neoadjuvant therapy demonstrates both safety and clinical feasibility for renal cell carcinoma patients with tumor thrombus
Neoadjuvant therapies can be safely administered to RCC patients with TT. Neoadjuvant therapies recipients' OS or CSS did not differ significantly from those who did not receive the treatment.
Authors
- Liyuan Ge (ORCID: https://orcid.org/0000-0002-5158-0311)
- Ye Yan (ORCID: https://orcid.org/0000-0002-7921-0101)
- Shaohui Deng (ORCID: https://orcid.org/0000-0001-9883-8570)
- Jianfei Ye (ORCID: https://orcid.org/0000-0003-4411-1573)
- Fan Zhang (ORCID: https://orcid.org/0000-0001-9293-7762)
- Guo‐Liang Wang (ORCID: https://orcid.org/0000-0001-8877-3064)
- Ke-Wei Chen (ORCID: https://orcid.org/0009-0002-3579-240X)
- Shudong Zhang (ORCID: https://orcid.org/0009-0001-3370-3365)
- Le Yu
Institutions
- Peking University (CN)
- Peking University Third Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1007/s12672-025-03489-w
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality